Rapt Therapeutics Inc.
RAPT Therapeutics Appoints Two New Directors to Its Board
Summary
On June 21, 2025, RAPT Therapeutics, Inc. expanded its Board of Directors from five to seven members by appointing Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., as new Class III directors. Dr. Braunstein, with over 30 years of experience in the biotech and pharmaceutical sectors, has served as President and CEO of Marinus Pharmaceuticals and currently sits on the boards of several other biotech companies. Dr. Dombkowski, with more than 20 years of experience as an operating executive and entrepreneur, has been the CEO of Cellics Therapeutics since November 2024. Both directors will receive compensation in line with the company's non-employee director policy and will be granted stock options as part of their compensation.
Profitelligence Alerts
Get alerts for RAPT
Be first to know when Rapt Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Rapt Therapeutics Inc.
Rapt Therapeutics Inc. is a biotechnology firm focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Its primary mission is to create novel treatments by harnessing its proprietary drug discovery platform, which targets key pathways responsible for the progression of these complex conditions. Rapt Therapeutics is notably advancing its development of selective inhibitors for immune checkpoint inhibitors within the broader cancer treatment landscape, potentially enhancing the efficacy of existing therapies. The company's pipeline includes multiple drug candidates tailored for specific types of cancer and chronic inflammatory disorders, underscoring its commitment to addressing unmet medical needs. By concentrating efforts on innovative approaches that modulate immune and inflammatory responses, Rapt Therapeutics plays a significant role in shaping the future of precision medicine in the biopharmaceutical industry. Founded in 2015 and leveraging advanced scientific insights, Rapt Therapeutics represents an important component of the biotech sector's efforts to push boundaries in disease treatment and improve patient outcomes.
Official SEC Documents
Advertisement